Summary: Todays consumers demand value, and the pharmaceutical industry is not immune. To transition from volume-based models to value-based pricing, companies must start with the basics: defining and measuring value. The latest episode of Deloitte Insights features Sean OGrady, moderator, Paul Keckley, executive director of Deloitte LLPs Center for Health Care Solutions, and Scott Evangelista, principal and national commercial leader of the Life Sciences Practice within Deloitte Consulting LLP. Tune in to learn more about how the new value-based economy is affecting the pharmaceutical industry.
